SynthesisClinical pharmacokinetics2012
Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies.
Synthesis in Clinical pharmacokinetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review.Intensive care medicine · 2014Pooled it
- Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function.The Cochrane database of systematic reviews · 2013Pooled it
- Fluid replacement with hydroxyethyl starch in critical care--a reassessment.Deutsches Arzteblatt international · 2013Pooled it
- Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis.Intensive care medicine · 2013Pooled it
- Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis.BMJ (Clinical research ed.) · 2013Pooled it
- Administration of HES in elderly patients undergoing hip arthroplasty under spinal anesthesia is not associated with an increase in renal injury.BMC anesthesiology · 2017Trial
- Fluids in the ICU: which is the right one?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Review
- Analysis of Molar Substitution of Hydroxybutyl Group by Zeisel Reaction in Starch Ethers.Molecules (Basel, Switzerland) · 2021Article
- Assessment of Hydroxyethyl Starch (6% HES 130/0.4) Kidney Storage in Critically Ill Dogs: A Post-mortem Prospective Study.Frontiers in veterinary science · 2021Article
- Effects of hydroxyethyl starch and gelatin on the risk of acute kidney injury following orthotopic liver transplantation: A multicenter retrospective comparative clinical study.Open medicine (Warsaw, Poland) · 2021Article
- Understanding the Harms of HES: A Review of the Evidence to Date.Turkish journal of anaesthesiology and reanimation · 2019Review
- Synthetic colloid resuscitation in severely injured patients: analysis of a nationwide trauma registry (TraumaRegister DGU).Scientific reports · 2018Article
- The effects of hydroxyethyl starch and gelatine on pulmonary cytokine production and oedema formation.Scientific reports · 2018Article
- Is the literature inconclusive about the harm from HES? No.Intensive care medicine · 2017Article
- Choice of Fluid Therapy in the Initial Management of Sepsis, Severe Sepsis, and Septic Shock.Shock (Augusta, Ga.) · 2016Review
- Modern resuscitation of hemorrhagic shock: what is on the horizon?European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2014Article
- Concerns over use of hydroxyethyl starch solutions.BMJ (Clinical research ed.) · 2014Article
- Hydroxyeyhyl starch: Controversies revisited.Journal of anaesthesiology, clinical pharmacology · 2014Review
- Fluid resuscitation in sepsis: reexamining the paradigm.BioMed research international · 2014Review
- Patient-centered outcomes and trials of hydroxyethyl starch.Critical care (London, England) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntravenously infused hydroxyethyl starch (HES) can be found in urine, plasma and tissues. HES remaining in plasma and tissues is thought to increase the risk of clinical complications. HES solutions of lower molecular weight and substitution have been developed to increase urinary excretion and reduce plasma persistence. However, their effect on tissue uptake of HES has not been investigated in human subjects.
objectiveOur objective was to test the hypothesis that lower molecular weight and substitution decrease tissue uptake of HES. DATA SOURCES: Computer searches were performed of MEDLINE; EMBASE; the Cochrane Library; meeting abstract databases in surgery, anaesthesiology and intensive care; ClinicalTrials.gov; and Google. Supplementary sources were reference lists and electronic tables of journal contents. No time period or language restrictions were imposed. STUDY SELECTION: Clinical studies were eligible for inclusion in the meta-analysis, if data were reported both for cumulative urinary excretion of HES over 24 hours after infusion and for plasma HES concentration at 24 hours. DATA EXTRACTION: Data were extracted on 24-hour urinary excretion of HES, 24-hour HES plasma concentration, plasma volume, HES molecular weight and substitution, study design, type and demographics of subjects, indication for fluid infusion, and HES infusion regimen. Tissue uptake of HES was computed as the difference between the infused dose and the sum of urinary excretion and residual plasma HES at 24 hours. DATA SYNTHESIS: Twenty-five clinical studies totalling 287 subjects were included. Tissue uptake of low-molecular-weight HES (≤200 kD) was 42.3% (95% confidence interval [CI] 39.6, 45.0) compared with 24.6% (CI 17.8, 31.4) for high-molecular-weight HES (p < 0.001). Similarly, tissue uptake of lower-substitution HES (≤0.5) was 42.4% (CI 39.5, 45.3) versus 26.6% (CI 19.6, 33.6) for higher-substitution HES (p < 0.001). Among the three most often investigated single HES solutions, tissue uptake of 130/0.4 (42.6%; CI 35.0, 50.2) and HES 200/0.5 (43.3%; CI 39.4, 47.2) closely coincided, whereas uptake of HES 450/0.7 (22.2%; CI 14.8, 29.6) was lower (p = 0.001 and p < 0.001, respectively).
conclusionsThis meta-analysis did not support the hypothesis that lower molecular weight and substitution decrease tissue uptake of HES. Further clinical studies of HES tissue uptake are needed.
Indexed as
Identifiers
22420578What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.